Polygenic risk scores predict diabetes complications and their response to intensive blood pressure and glucose control.
Johanne Tremblay, Mounsif Haloui, Redha Attaoua...
https://pubmed.ncbi.nlm.nih.gov/34226943/Actively Recruiting
Led by Optithera · Updated on 2024-09-19
2714
Participants Needed
2
Research Sites
52 weeks
Total Duration
This research aims to provide Real World Evidence on how knowing the results of a polygenic risk prediction test affects the management of heart and kidney complications in adults with type 2 diabetes T2D. The study compares patients who are informed of their genetic risk score with those who are not, evaluating whether this knowledge helps more patients meet recommended treatment goals over an 18-month period. Researchers focus on key health measures such as blood sugar, blood pressure, and kidney function to assess these outcomes. Participants are randomly assigned to two groups one group receives their polygenic risk score results at the start of the study, while the other group is tested but not initially informed of their results. The study involves saliva sampling for genetic testing, followed by regular clinic visits every three months for a total of seven visits over 18 months. During these visits, patients undergo health checkups and complete quality of life questionnaires. Throughout the study, researchers monitor participants blood sugar levels HbA1c, systolic blood pressure, urine albumin levels, and kidney filtration rates to see if treatment targets are better achieved with knowledge of genetic risk. Medication use for blood pressure, glucose, and lipids is also tracked. The study includes safety measures such as avoiding severe hypoglycemia and falls, with ongoing assessments at each visit to observe health changes over time.
CONDITIONS
Clinical Utility of a Genomic Predictor Test on the Management of Cardiorenal Complications of Type 2 Diabetes
M
Marie-Renée Guertin, il,cra
J
Johanne Tremblay, PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Optithera
Lead Sponsor
Genome Quebec
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - At start of study
Participants undergo testing with the Polygenic Risk Score device to estimate their risk of developing cardiorenal complications of type 2 diabetes. Some participants are informed of their results at the start, while others are not initially informed.
1 visit (in-person)
Duration - 18 months
Participants are followed for 18 months to monitor their blood pressure, blood glucose, albuminuria, and kidney function to assess the impact of knowing their risk score on managing type 2 diabetes complications.
7 visits over 18 months
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Johanne Tremblay, Mounsif Haloui, Redha Attaoua...
https://pubmed.ncbi.nlm.nih.gov/34226943/Optithera
Lead Sponsor
Genome Quebec
Collaborating Sponsor